Last reviewed · How we verify
Primovist (GADOXETIC ACID)
Primovist (generic name: GADOXETIC ACID) is a Paramagnetic Contrast Agent drug. It is currently FDA-approved (first approved 2008).
Gadoxetic acid (Primovist) is a marketed contrast agent with a key composition patent expiring in 2028. Its primary competitive advantage lies in its unique mechanism of action, which enhances liver lesion detection compared to other same-class agents. The primary risk is the strong competition from established generics like gadoteridol, which may erode market share post-patent expiry.
At a glance
| Generic name | GADOXETIC ACID |
|---|---|
| Drug class | Paramagnetic Contrast Agent |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
Common side effects
Key clinical trials
- Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment (NA)
- A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer (PHASE2)
- Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis (PHASE4)
- REGULUS: MRI-guided Adaptive SABR for Liver Cancers (PHASE2)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions (NA)
- PET/MRI of Primary Sclerosing Cholangitis
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Primovist CI brief — competitive landscape report
- Primovist updates RSS · CI watch RSS
Frequently asked questions about Primovist
What is Primovist?
What is the generic name of Primovist?
What drug class is Primovist in?
When was Primovist approved?
What development phase is Primovist in?
Related
- Drug class: All Paramagnetic Contrast Agent drugs
- Therapeutic area: All drugs in Gastroenterology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing